Glycogen storage disease type II (Pompe disease)

  • PTA17333 Avaglucosidase: A French multicenter Phase 4 open label extension study of long -term safety and efficacy in patients with Pompe disease who previously participated in avalglucosidase development studies in France.
  • French Pompe disease register
  • International Pompe Disease Register

 

Acronym

PTA17333 Avaglucosidase

French Pompe disease register

International Pompe disease register

Intervention Avalglucosidase alpha
Principal investigator Anthony Behin Pascal Laforet Pascal Laforet
Sponsor Sanofi Institute of Myology Sanofi
Study status Active Active Active
Recruitment status Completed
Population Adult Adult Adult
  + infos on clinicaltrials.gov
Contact essais-adultes@institut-myologie.org